EC Number |
Inhibitors |
Structure |
---|
3.5.1.60 | (2E)-3-([1,1'-biphenyl]-4-yl)-1-(pyrrolidin-1-yl)prop-2-en-1-one |
a reversible and competitive NAAA inhibitor, that shows in vivo anti-inflammatory activity, the pyrrolidine ring of 4g occupies the enzyme catalytic center of NAAA, preventing the carbonyl group from forming a covalent bond with catalytic residues |
|
3.5.1.60 | (2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)penta-2,4-dien-1-one |
- |
|
3.5.1.60 | (2R)-2-hydroxy-N-pentadecyl-2-phenylacetamide |
- |
|
3.5.1.60 | (2S)-2-hydroxy-N-pentadecyl-2-phenylacetamide |
- |
|
3.5.1.60 | (2S)-2-hydroxy-N-pentadecyl-2-phenylacetamide |
a covalent beta-lactam |
|
3.5.1.60 | (7E)-N-[(3S)-2-oxoazetidin-3-yl]non-7-enamide |
- |
|
3.5.1.60 | (S)-2-oxo-3-oxetanyl-carbamic acid benzyl ester |
a serine-derived beta-lactone, weak inhibition of rat lung enzyme, structure-activity relationship studies confirm that the ability of the compound to inhibit the enzyme depends on the beta-lactone ring, rather than the carbamate fragment, because analogues lacking the beta-lactone moiety are devoid of inhibitory activity |
|
3.5.1.60 | (Z)-N-[(S)-2-oxoazetidin-3-yl]non-3-enamide |
- |
|
3.5.1.60 | ([1,1'-biphenyl]-4-yl)methyl cyclopentanecarboxylate |
- |
|
3.5.1.60 | ([1,1'-biphenyl]-4-yl)methyl [(2S,3R)-2-methyl-4-oxooxetan-3-yl]carbamate |
inhibition through a rapid and noncompetitive mechanism, partially reversible inhibition. The compound reacts with the catalytically active N-terminal Cys126 of human enzyme to form a thioester bond |
|